Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by Claridgeon Jun 15, 2019 4:59pm
97 Views
Post# 29829322

About the upcoming next 3 canadian sites to join Ph. 2b ...

About the upcoming next 3 canadian sites to join Ph. 2b ...The 3 canadian sites that are in final discussions come from this type of consortium:

PHASE 2 CLINICAL TRIAL CONSORTIUM

Established in 2001, The Princess Margaret's Phase 2 Clinical Trial Consortium is one of seven sites – and the only site outside of the U.S. – to have received funding by the National Cancer Institute. Led by Dr. Amit Oza, the consortium's mandate is to develop leading-edge clinical trials through collaboration with other cancer centres across Canada.

Through that mechanism, we created a network so we could efficiently conduct early phase clinical trials. We have been able to successfully bring cancer agents in the earliest of developmental stages to the clinical trial settings, which would otherwise be unavailable to Canadian patients,” says Dr. Oza. “For nearly two decades we have been able to develop, design and execute clinical trials with a high degree of rigour and contribute important new knowledge regarding the biology of cancer that has helped change the paradigm of care in several cancer types.” Through that mechanism, more than 100 clinical trials have been conducted over the past 15 years.

Bullboard Posts